Ebbinghaus Joins Fox Chase Cancer Center’s Medical Oncology Staff
PHILADELPHIA (August 5, 2008)—Scot W. Ebbinghaus, MD, of Lansdale, PA, a board-certified medical oncologist specializing in lung cancer, recently joined Fox Chase Cancer Center. He comes to the Philadelphia region from the University of Arizona and Arizona Cancer Center in Tucson, where he was an associate professor of hematology and oncology.
“I am excited to be on staff at Fox Chase because as a freestanding cancer center, Fox Chase is very patient-oriented, Ebbinghaus said. “I am committed to providing patients with the most optimal treatments available to treat lung cancer.
“I encourage my patients to be optimistic because treatment options are usually available; are better than yesterday; and will be even better in the near future,” he added.
Ebbinghaus has served as principal investigator for several clinical trials involving patients with lung, kidney and other cancers. He has published some 30 professional journal papers and textbook chapters and has made frequent presentations at national meetings of the American Society of Clinical Oncology, the American Association for Cancer Research and other professional groups.
In addition to being an attending physician at Fox Chase, Ebbinghaus holds the position of medical director of oncology clinical research at pharmaceutical firm Merck & Co. in Upper Gwynedd, Pa.
Ebbinghaus earned undergraduate and medical degrees in a combined BA/MD program at the University of Missouri at Kansas City and was elected to the Alpha Omega Alpha medial honor society. He completed his residency in internal medicine and a fellowship in hematology and oncology at the University of Alabama at Birmingham, where he earned several awards for excellence in cancer research.
He was assistant professor of medicine at University of Alabama before joining the University of Arizona faculty.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.